Abstract
Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1321-1323 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 69 |
| Issue number | 11 |
| State | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Phase II trial of mitoxantrone in multiple myeloma : A southwest oncology group study. / Alberts, David S; Balcerzak, S. P.; Bonnet, J. D.; Stephens, R. L.
In: Cancer Treatment Reports, Vol. 69, No. 11, 1985, p. 1321-1323.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of mitoxantrone in multiple myeloma
T2 - A southwest oncology group study
AU - Alberts, David S
AU - Balcerzak, S. P.
AU - Bonnet, J. D.
AU - Stephens, R. L.
PY - 1985
Y1 - 1985
N2 - Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.
AB - Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.
UR - http://www.scopus.com/inward/record.url?scp=0022406156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022406156&partnerID=8YFLogxK
M3 - Article
C2 - 4092195
AN - SCOPUS:0022406156
VL - 69
SP - 1321
EP - 1323
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 11
ER -